"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...
According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...
Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.
By Dennis Thompson HealthDay ReporterWEDNESDAY, Jan. 7, 2026 (HealthDay News) — Ozempic and Wegovy might help people avoid ...
Experts say OADs, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, ...
Novo Nordisk is the first manufacturer to market its drug Wegovy in pill form in the U.S., though Eli Lilly expects approval ...
Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...
Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...
Stocktwits on MSN
Altimmune receives FDA’s breakthrough therapy designation for its liver disease drug
Altimmune, Inc. (ALT) announced on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation ...
Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk ...
At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback